A 28-week, randomised, open-label, parallel-group, multi-center study to find the effective dose of candesartan cilexetil (Atacand) for renoprotection in Korean hypertensive patients with non-diabetic nephropathy.

Trial Profile

A 28-week, randomised, open-label, parallel-group, multi-center study to find the effective dose of candesartan cilexetil (Atacand) for renoprotection in Korean hypertensive patients with non-diabetic nephropathy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Aug 2011

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Hypertension; Proteinuria
  • Focus Therapeutic Use
  • Acronyms ARIA; PCR
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Sep 2009 Additional trial acronym PCR identified as reported by ClinicalTrials.gov.
    • 16 Sep 2009 Actual end date (1 Aug 2009) added as reported by ClinicalTrials.gov.
    • 16 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top